Business
Notice of FY22 Results and Investor Webinar
Notice of FY22 Results and Investor Webinar.
About this update from Oxford Biodynamics Plc
[{"type":"text","content":"\n \n \n \n Oxford BioDynamics Plc\n \n \n \n \n (\n \n \"OBD\" or the \"Company\" and, together with its subsidiaries, the \"Group\")\n \n \n \n \n \n \n \n \n Notice of Results and Investor Webinar\n \n \n \n \n 21 December 2022 -\n \n Oxford BioDynamics Plc (AIM: OBD, the Company), a biotechnology company developing precision medicine tests for immune health based on the EpiSwitch® 3D genomics platform expects to announce its results for the year ended 30 September 2022 on Tuesday 24 January 2023.\n \n \n Following release of the results, the Company's management team will conduct a live presentation via the Yellowstone Advisory webinar platform to investors, at 2pm GMT on Tuesday 24 January 2023.\n \n \n The online presentation is open to both existing and potential shareholders. Questions will be addressed at the end of the presentation and may be submitted either before the presentation by emailing\n \n \n [email protected]\n \n \n or during the presentation.\n \n \n To register for the presentation, please visit: \n \n \n https://us02web.zoom.us/webinar/register/8016711901502/WN_BdNuLMzhT8KBzPJUHHEvng\n \n \n \n \n \n -Ends-\n \n \n \n \n \n \n \n \n \n For further details please contact:\n \n \n \n \n \n \n \n \n \n \n \n Oxford BioDynamics Plc\n \n \n \n Jon Burrows, CEO\n \n \n Paul Stockdale, CFO\n \n \n \n \n \n \n \n Tel:\n +44 (0)1865 518910\n \n \n \n \n \n \n \n Shore Capital - Nominated Adviser and Broker\n \n \n \n Advisory: Stephane Auton / John More\n \n \n Broking: Fiona Conroy\n \n \n \n \n \n \n \n Tel:\n +44 (0)20 7408 4090\n \n \n \n \n \n \n \n Instinctif Partners\n \n \n \n Melanie Toyne-Sewell / Rozi Morris / Adam Loudon\n \n \n \n \n Tel: +44 (0)20 7457 2020\n \n \n [email protected]\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n Notes for Editors\n \n \n \n \n \n \n \n \n About Oxford BioDynamics Plc\n \n \n Oxford BioDynamics Plc (AIM: OBD) is a global biotechnology company, advancing personalized healthcare by developing and commercializing precision medicine tests for life-changing diseases.\n \n \n Its flagship product is\n \n \n \n EpiSwitch® CiRT\n \n \n (Checkpoint Inhibitor Response Test) for cancer, a predictive immune response profile for immuno-oncology (IO) checkpoint inhibitor treatments, la...